Tarveda Therapeutics

Tarveda Therapeutics is a biopharmaceutical company founded in 2012 with a mission to develop and commercialize a new class of potent and selective precision oncology medicines. The company's flagship technology, Pentarin® miniature drug conjugates, is designed to effectively treat patients with various solid tumor malignancies by deeply penetrating solid tumors and selectively binding to the desired tumor targets. The company's first clinical program, PEN-866, is a promising candidate targeting the Heat Shock Protein 90 (HSP90), which is highly activated in the tumor environment. With the recent $6.00M Venture Round investment obtained on 27 September 2021, Tarveda is continuing its Phase 2a trial for PEN-866 in various types of solid tumors and further expanding its development of miniature drug conjugates to target other promising anti-cancer payloads. This consistent advancement positions Tarveda Therapeutics as a key player in the biotechnology and healthcare industries, offering potential for significant impact in precision oncology treatment.